Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a ...

Wedbush raised the firm’s price target on Janux Therapeutics (JANX) to $76 from $75 and keeps an Outperform rating on the shares following ...

Equities research analysts at Wedbush issued their FY2027 earnings per share estimates for AMC Entertainment in a report ...

Dan Ives, Global Head of Technology Research at Wedbush Securities, talks about how Deepseek has transformed China's role in ...

Wedbush analyst Matt Bryson lowered the firm’s price target on NetApp (NTAP) to $110 from $120 and keeps a Neutral rating on the shares. After ...

Wedbush Securites, a 70-year-old financial services firm based in Los Angeles, has filed with the Securities and Exchange ...

Dan Ives, Wedbush global head of technology research, joins 'Power Lunch' to discuss Apple's U.S. investment and Microsoft's ...

Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, ...

It's been a volatile and interesting year for Tesla ( TSLA 3.91%) stock, its CEO, Elon Musk, and its various businesses. The ...

Detailed price information for Palantir Technologies Inc Cl A (PLTR-Q) from The Globe and Mail including charting and trades.

As mentioned, Palantir has declined 32% from its record high in the last seven trading days, but the statistics suggest the ...

Wedbush analyst Nick Setyan downgraded the shares of Dine Brands Global Inc (NYSE:DIN) from Outperform to Neutral and lowered ...